Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the gene expression and activity of SIRT1, and forkhead box O3 pathway by means of investigating target genes MnSOD and catalase in multiple sclerosis and healthy subjects. Also, we investigate the effect of melatonin on interaction between SIRT1 activity and target genes MnSOD and catalase in multiple sclerosis and healthy subject .Additionally, we evaluate effect the probable effect of melatonin treatment on gene expression and activity of above-mentioned genes in peripheral blood mononuclear cells of healthy subjects-treated with H2O2.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Multiple slerosis | Experimental | Melatonin,,one millimolar,one micromolar,one nanomolar, 12 hr treatment. |
|
| Healthy subjects | Experimental | Melatonin,one millimolar,one micromolar,one nanomolar, 12 hr treatment. hydrogen peroxide, 250 micromollar,2 hr treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Melatonin | Drug | Melatonin is used for healthy subjects and multiple sclerosis patients |
|
| Measure | Description | Time Frame |
|---|---|---|
| Relative gene expression by real-time PCR (polymerase chain reaction) | Change from baseline after 12-hour treatment with melatonin and 2 -hours treatment with H2O2 |
| Measure | Description | Time Frame |
|---|---|---|
| MnSOD enzyme activity assay | Change from baseline after 12-hour treatment with melatonin and 2 -hours treatment with H2O2 | |
| Catalse enzyme activity assay | Change from baseline after 12-hour treatment with melatonin and 2 -hours treatment with H2O2 |
Not provided
Inclusion Criteria:
patients with relapsing-remitting multiple sclerosis. The diagnosis of MS was based on the McDonald criteria . All patients were newly diagnosed cases with an Expanded Disability Status Scale (EDSS) score ≤ 6 and had never received immunomodulatory and immunosuppressive drugs.
-
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mohammad Ali Sahraian, Neurologist | Tehran University of Medical Sciences | Study Director |
| Solaleh Emamgholipour, PhD Student | Tehran University of Medical Sciences | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Solaleh Emamgholipour | Tehran | Iran |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Hydrogen peroxide | Other | Hydrogen peroxide is only used for healthy subjects |
|
| SIRT1 enzyme activity assay | Change from baseline after 12-hour treatment with melatonin and 2 -hours treatment with H2O2 |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008550 | Melatonin |
| D006861 | Hydrogen Peroxide |
| ID | Term |
|---|---|
| D014363 | Tryptamines |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D010545 | Peroxides |
| D010087 | Oxides |
| D000838 | Anions |
| D007477 | Ions |
| D004573 | Electrolytes |
| D007287 | Inorganic Chemicals |
| D017382 | Reactive Oxygen Species |
| D005609 | Free Radicals |
| D017601 | Oxygen Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided